Enhancing COVID-19 Vaccines Acceptance: Results from a Survey on Vaccine Hesitancy in Northern Italy.
COVID-19
Italy
SARS-CoV-2
classification tree
past vaccination refusal
risk perception
survey
vaccine hesitancy
vaccine hesitancy predictors
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
13 Apr 2021
13 Apr 2021
Historique:
received:
12
03
2021
revised:
09
04
2021
accepted:
11
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
In March 2021, the coronavirus disease 2019 (COVID-19) pandemic still poses a threat to the global population, and is a public health challenge that needs to be overcome. Now more than ever, action is needed to tackle vaccine hesitancy, especially in light of the availability of effective and safe vaccines. A cross-sectional online survey was carried out on a representative random sample of 1011 citizens from the Emilia-Romagna region, in Italy, in January 2021. The questionnaire collected information on socio-demographics, comorbidities, past vaccination refusal, COVID-19-related experiences, risk perception of infection, and likelihood to accept COVID-19 vaccination. Multiple logistic regression analyses and classification tree analyses were performed to identify significant predictors of vaccine hesitancy and to distinguish groups with different levels of hesitancy. Overall, 31.1% of the sample reported hesitancy. Past vaccination refusal was the key discriminating variable followed by perceived risk of infection. Other significant predictors of hesitancy were: ages between 35 and 54 years, female gender, low educational level, low income, and absence of comorbidities. The most common concerns about the COVID-19 vaccine involved safety (54%) and efficacy (27%). Studying the main determinants of vaccine hesitancy can help with targeting vaccination strategies, in order to gain widespread acceptance-a key path to ensure a rapid way out of the current pandemic emergency.
Identifiants
pubmed: 33924534
pii: vaccines9040378
doi: 10.3390/vaccines9040378
pmc: PMC8070202
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Epidemiol. 2020 Aug;35(8):775-779
pubmed: 32785815
Ann Intern Med. 2020 Dec 15;173(12):964-973
pubmed: 32886525
Vaccine. 2020 Jan 16;38(3):482-488
pubmed: 31718899
Int J Environ Res Public Health. 2021 Jan 19;18(2):
pubmed: 33477825
Am J Prev Med. 2015 Dec;49(6 Suppl 4):S391-8
pubmed: 26337116
N Engl J Med. 2021 Apr 22;384(16):1483-1487
pubmed: 33657291
Vaccines (Basel). 2021 Mar 03;9(3):
pubmed: 33802285
Vaccines (Basel). 2021 Jan 12;9(1):
pubmed: 33445581
Pediatrics. 2020 Jul;146(1):
pubmed: 32540985
Vaccines (Basel). 2020 Oct 01;8(4):
pubmed: 33019663
Eur J Health Econ. 2020 Sep;21(7):977-982
pubmed: 32591957
Am J Prev Med. 2021 Jan;60(1 Suppl 1):S24-S33
pubmed: 33131990
Lancet Public Health. 2021 Apr;6(4):e210-e221
pubmed: 33556325
Soc Sci Med. 2021 Mar;272:113688
pubmed: 33485215
Vaccine. 2020 Sep 29;38(42):6500-6507
pubmed: 32863069
Vaccines (Basel). 2020 Dec 30;9(1):
pubmed: 33396832
Vaccine. 2021 Feb 12;39(7):1080-1086
pubmed: 33461833
EClinicalMedicine. 2020 Sep;26:100495
pubmed: 32838242
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
Eur J Public Health. 2020 Apr 1;30(2):286-292
pubmed: 31746999
Vaccine. 2015 Aug 14;33(34):4180-90
pubmed: 25896377
Prev Med. 2019 Jun;123:278-287
pubmed: 30904601
PLoS One. 2021 May 12;16(5):e0251095
pubmed: 33979370
Lancet Public Health. 2021 Apr;6(4):e195-e196
pubmed: 33556329
Front Psychol. 2020 Oct 19;11:575950
pubmed: 33192883
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Vaccines (Basel). 2021 Jan 18;9(1):
pubmed: 33477725